CVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CVS Health Corp is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong financial performance, strategic partnerships, and diversified business model outweigh the recent Medicare Advantage reimbursement concerns. The stock is trading at a reasonable level, and the long-term growth prospects remain intact.
The technical indicators are mixed but leaning slightly bullish. The MACD is positive and contracting, RSI is neutral, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 77.649, with key resistance at 80.999 and support at 74.299.
Strategic partnership with Google Cloud to launch Health100, aiming to enhance healthcare services and consumer engagement using AI.
Strong financial performance in Q4 2025 with revenue up 8.17% YoY, net income up 79.01% YoY, and EPS up 76.15% YoY.
Analysts maintain a generally positive outlook, with multiple Buy ratings and price targets ranging from $90 to $101.
Concerns over Medicare Advantage reimbursement rates for 2027, which could impact revenue and margins.
Gross margin dropped by 2.73% YoY in Q4 2025, indicating some cost pressures.
In Q4 2025, CVS Health reported strong financial growth: Revenue increased by 8.17% YoY to $105.69 billion, net income surged by 79.01% YoY to $2.94 billion, and EPS rose by 76.15% YoY to $2.29. However, gross margin declined by 2.73% YoY to 12.84%, which may indicate rising costs.
Analysts maintain a positive outlook on CVS Health. Recent ratings include multiple Buy and Outperform ratings, with price targets ranging from $90 to $101. Analysts acknowledge potential headwinds from Medicare Advantage reimbursement rates but believe CVS's diversified business model can mitigate these risks. Long-term growth prospects remain strong, with mid-teens EPS growth projected through 2028.
